drugset / Trial / NCT07564466

A Study of SKB571 in Participants With Gastrointestinal Tumors

NCT07564466

Phase 2 Not yet recruiting 120 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.

Timeline

Start
2026-06-30
Primary completion
2027-08-31
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SKB571 Unknown Intravenous